Kimberly-Clark is buying Tylenol maker Kenvue for nearly $50 billion, and Wall Street isn’t too fond of the deal. And for good reason. The cash-and-stock transaction, announced Monday, values Kenvue …
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.
view original post